**Core Concept:** Addison disease is an autoimmune disorder where the adrenal glands produce insufficient amounts of cortisol and aldosterone. Hypoparathyroidism is characterized by low levels of parathyroid hormone (PTH) resulting in low calcium levels and high phosphate levels. Mucocutaneous candidiasis is an infection caused by overgrowth of Candida species, often seen in patients with compromised immune systems, such as those on long-term steroid therapy.

**Why the Correct Answer is Right:** The correct answer is C. Autoimmune diseases often present together in patients due to the shared pathophysiology. In the case of Addison disease, the immune system mistakenly attacks the adrenal glands, leading to insufficient cortisol and aldosterone production. Hypoparathyroidism, on the other hand, is caused by the immune system attacking the parathyroid glands, resulting in low PTH levels and subsequent hypocalcemia and hyperphosphatemia. Mucocutaneous candidiasis is a manifestation of the compromised immune system in such patients, as the overgrowth of Candida species is a reflection of the patient's inability to combat these infections due to low calcium levels and/or cortisol suppression.

**Why Each Wrong Option is Incorrect:**

A: Addison disease presenting alone without hypoparathyroidism and mucocutaneous candidiasis is possible but less likely due to the association mentioned above.
B: Hypoparathyroidism alone is not associated with mucocutaneous candidiasis unless secondary to steroid therapy or other immunosuppressive treatments.
D: Mucocutaneous candidiasis is not typically seen with primary hypoparathyroidism alone or in combination with primary adrenal insufficiency (Addison disease).

**Clinical Pearl:** Patients with Addison disease and hypoparathyroidism, particularly those on long-term steroid therapy, are at a higher risk for mucocutaneous candidiasis due to their compromised immune systems. Regular screening and prompt treatment of these infections are essential to prevent complications and improve patient outcomes. In such cases, the patient should be treated with calcium and vitamin D supplements to prevent hypocalcemia-induced neuromuscular manifestations and maintain immune function.